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adolescents (13–18 years). The effect of combination therapy on risk of weight gain 
was observed against both SSRI monotherapy and SGA monotherapy in multivariable 
logistic regression analyses. Likelihood of gaining weight with combination therapy 
was higher against both SSRI monotherapy (OR = 1.88; 1.69–2.10) and SGA mono-
therapy (OR = 1.52; 1.37–1.68). Long-term combination therapy (>60 days of treat-
ment overlap) resulted into increased risk of weight gain (OR = 1.64; 1.30–2.07) as 
compared to short term uses (> = 14 days and <60 day). CONCLUSIONS: The effect 
of combination therapy on increased risk of weight gain was suggested in the study, 
especially when the combinations were used for long term maintenance. Comprehen-
sive evaluation of other psychotropic combinations on risk of other adverse events is 
needed to be conducted in future.
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OBJECTIVES: Monitoring maternal morbidity is essential as per Healthy People 2010 
objectives. Maternal morbidity due to pre-existing medical conditions (PEC’s) is found 
to be an important determinant of delivery complications. With limited literature for 
the inﬂuence of PEC’s on obstetric hospitalization, the objective of this study was to 
assess the effects of PEC’s on length of stay (LOS) during child delivery. METHODS: 
The 2006 National Hospital Discharge Survey (NHDS) was used as the data source. 
PEC’s included diagnosis of chronic hypertension, diabetes mellitus, anemia, asthma, 
thyroid disorder or cardiac disease before conception. Cox Proportional Hazards 
Model was performed to ascertain the relationship between PEC’s and LOS in the 
presence of other covariates. The data analysis was conducted using SAS 9.1. 
RESULTS: The 2006 NHDS included records of 39,751 women hospitalized for child 
birth; of which 15.25% (N = 6,063) had diagnosis of one or more PEC’s in contrast 
to 4.9% in early 2000’s. PEC’s group had higher proportion of older women 
(≥35years) (20.32% vs. 16.43%, p < 0.0001) and African-Americans (23.50% vs. 
15.79%, p < 0.0001) compared to the non-PEC’s group. Presence of PEC’s was found 
to be associated with prolonged LOS (hazard ratio = 0.840, p < 0.0001). Among 
hospital characteristics, women delivering in large hospitals (≥500beds) (hazard ratio 
= 0.880, p < 0.0001) and northeastern and southern regions (hazard ratio = 0.813, p 
< 0.0001) had extended LOS. In addition, African-American race (hazard ratio = 
0.863, p < 0.0001) and cesarean delivery (hazard ratio = 0.383, p < 0.0001) were also 
associated with longer LOS. CONCLUSIONS: Women with PEC’s impose signiﬁcant 
health care burden in terms of length of stay during child birth. Access to appropriate 
pre-conception and prenatal care should be ensured to childbearing women, especially 
due to the rising prevalence of PEC’s. Racial and geographical disparities need to be 
examined by policy-makers while framing prophylactic strategies. Future research 
should assess the health care resource utilization due to maternal morbidity from 
pre-conception to postpartum period.
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DIAGNOSIS AND TREATMENT OF WOMEN WITH HYPOACTIVE 
SEXUAL DESIRE DISORDER AND DEPRESSION/ANXIETY
Johnson BH1, Palmer L2, Foley D3
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Washington, DC, USA, 
3Boehringer-Ingelheim, Ridgeﬁeld, CT, USA
OBJECTIVES: The goal of this study is to describe the timing of the Hypoactive Sexual 
Desire Disorder (HSDD) diagnosis with that of depression/anxiety in a subgroup of 
women suffering from both disorders and determine which diagnosis came ﬁrst—
depression/anxiety or HSDD. In addition it describes the use of both antidepressants 
and anxiolytics in this subgroup. METHODS: Marketscan® Research Databases were 
used to identify women aged 18–64 with an ICD-9-CM coded diagnosis of HSDD 
(302.71) from January 1, 1998-December 31, 2007 who also had an ICD-9-CM coded 
diagnosis of depression or anxiety (293.84, 296.2x, 296.3x, 300.0x, 300.4, 309.1, 
311, v79.0). The ﬁrst physician visit with an HSDD diagnosis was the index date. 
Antidepressant and anxiolytic use was examined in the 24-month study period (12-
months before and following index). RESULTS: A total of 957 (24.1%) of 3,975 
women identiﬁed with HSDD also had a diagnosis of anxiety or depression in the 
study period. In this group, 34.7% (n = 332) had a depression/anxiety-coded claim 
appear after their HSDD-coded claim (after cohort), conversely, 65.3% (n = 625) had 
a depression/anxiety-coded claim appear on or before their HSDD-coded claim (before 
cohort). The majority of women in both the after and before cohorts were prescribed 
an antidepressant or anxiolytic in the study period, 78.3% (n = 260) and 86.1% (n 
= 538) respectively. Sixty percent (n = 156) and sixty-ﬁve percent (n = 351) of these 
women went on to discontinue use of the same. CONCLUSIONS: Over 24% of 
women with HSDD also suffer with depression/anxiety. More than one-third of these 
women developed their depression/anxiety diagnosis after being diagnosed with 
HSDD. A larger proportion of women had a diagnosis of depression and/or anxiety 
on or before that of HSDD. This may be evidence that both depression/anxiety and 
HSDD often present in tandem and that doctors feel competent to make such diag-
noses concurrently. Additionally, intervention with antidepressants or anxiolytics 
appear inadequate to treat this population.
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OBJECTIVES: We sought to evaluate the prevalence of polypharmacy, and to deter-
mine patient characteristics that are predictive of exposure to polypharmacy in the 
elderly population of Emilia-Romagna, Italy. METHODS: We conducted a retrospec-
tive cohort study of the 2007 Emilia-Romagna outpatient pharmacy database linked 
with patient information available from a demographic ﬁle of approximately 1 million 
Emilia-Romagna residents aged ≥65 years. The cohort was comprised of 887,165 
elderly patients who had at least one prescription ﬁlled during the study year. Using 
the World Health Organization’s Deﬁned Daily Dose (DDD) to determine the duration 
of treatment for a given drug, we deﬁned a polypharmacy episode as overlapping 
treatment with 5 or more medications occurring for at least one day. The prevalence 
of polypharmacy was measured together with patient characteristics found to be 
predictive of polypharmacy exposure. RESULTS: A total of 349,689 elderly in the 
population (39.4%) were exposed to at least one episode of polypharmacy. The 
prevalence of polypharmacy substantially increased with age, (32.7% for those ages 
65–74, over 45% for those ages 75+). Over 35% of those exposed to polypharmacy 
were exposed for 101 or more days of the year. The top three classes of medications 
involved in polypharmacy were antithrombotics, peptic ulcer disease and gastro-
esophageal reﬂux disease agents, and angiotensin-converting enzyme inhibitors. Com-
pared to unexposed subjects, elderly exposed to polypharmacy were older, were more 
likely to be male, and had a greater number of chronic conditions. CONCLUSIONS: 
This study provides evidence that the prevalence of polypharmacy in the elderly in 
Emilia-Romagna is substantial. Educational programs targeting primary care physi-
cians should be developed to make them aware of the magnitude of polypharmacy 
phenomenon, as well of patient characteristics associated with polypharmacy to ensur-
ing safe, effective, and appropriate use of medication in the elderly population.
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OBJECTIVES: Non-medical use of prescription drugs (NMPUD) is a serious problem 
in the US. This problem is even more concerning among pregnant women since non-
medical use of prescription drugs has the potential to harm both mother and fetus. 
However, our knowledge about the prevalence of NMPUD among pregnant women 
and its predictors is limited. This study attempted to ﬁll these gaps. Objectives of this 
study were: 1) To estimate the prevalence of NMUPD among pregnant women, and 
2) To determine various predictors of NMUPD among pregnant women. METHODS: 
This study used data from 2007 National Survey on Drug Use and Health (NSDUH). 
Sample consisted of non-institutionalized, pregnant women who were 12 years or 
older. Multiple logistic regression analyses which adjusted for the complex survey 
design were conducted to estimate the relationship between NMUPD among pregnant 
women and demographic characteristics. RESULTS: The sample consisted of 956 
respondents out of which 92 (9.62%) had engaged in NMUPD in the past year. 
Among different categories of prescription drugs, prevalence of non-medical use was 
highest for pain relievers (5.27%), followed by tranquilizers (1.65%), stimulants 
(1.93%), and sedatives (0.51%). Results from the logistic regression showed signiﬁ-
cant relationships between past year NMUPD and poor health status (O.R. = 5.28, 
95% CI: 1.37–20.28), past year use of tobacco (O.R. = 2.28, 95% CI: 1.003–5.226), 
and African American race (O.R. = 0.19, 95% CI: 0.06–0.52) or other nonwhite races 
(O.R. = 0.08, 95% CI: 0.02–0.29) at α = 0.05. CONCLUSIONS: Pain relievers are 
used most frequently non-medically by pregnant women when compared to the other 
prescription drugs. Pregnant women, who are white, have poorer health and those 
who smoke are more likely to engage in NMUPD than the others. This study highlights 
the group of pregnant women that are more vulnerable to NMUPD. Physician need 
to be careful while prescribing medication to these high risk groups.
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OBJECTIVES: It is assumed within the context of clinical trials that the measurement 
characteristics of self-report outcomes are equivalent. However, little work has been 
conducted to determine if this assumption is supported. The goal of the current study 
was to determine trial allocation may signiﬁcantly impact on the psychometric proper-
ties of a commonly used self-report postnatal depression screening questionnaire. 
METHODS: Utilising data from a prospective randomised controlled trial (RCT) 
investigating the impact of antenatal exercise on psychological well-being, postnatal 
depression was assessed using the Edinburgh Postnatal Depression Scale (EPDS) at the 
12–16 weeks following birth. Structural equation modeling approaches were used to 
investigate the assumption of measurement invariance of the EPDS using a two-
